Minagar MD / Minagar Neurobiology of Dementia

1. Auflage 2009
ISBN: 978-0-08-088878-1
Verlag: Elsevier Science & Techn.
Format: EPUB
Kopierschutz: 6 - ePub Watermark

E-Book, Englisch, Band Volume 84, 359 Seiten

Reihe: International Review of Neurobiology

With recent advances of modern medicine, more people reach the 'elderly age” around the globe, and the number of dementia cases are ever increasing. This book is about various aspects of dementia and provides its readers with a wide range of thought-provoking sub-topics in the field of dementia. The ultimate goal of this monograph is to stimulate other physicians' and neuroscientists' interest to carry out more research projects into the pathogenesis of this devastating group of diseases.

Autoren/Hrsg.

Minagar MD, Faan

Minagar, Alireza

Inhaltsverzeichnis

1;Front Cover;1
2;Neurobiology of Dementia;4
3;Copyright Page;5
4;Contents;6
5;Contributors;12
6;Preface;16
7;Chapter 1: Normal Brain Aging: Clinical, Immunological, Neuropsychological, and Neuroimaging Features;18
7.1;I. Introduction;19
7.2;II. Epidemiology of Aging: Risks and Implications;19
7.3;III. Normal Aging and Functional Performance;22
7.4;IV. T- and B-Lymphocyte Loss of Function in the Aging Immune System;24
7.5;V. Neuropsychology of Aging;26
7.6;VI. Imaging Studies in Aging;28
7.7;References;31
8;Chapter 2: Subcortical Ischemic Cerebrovascular Dementia;38
8.1;I. Terminology;39
8.2;II. Various Classifications of "Vascular" Dementia;39
8.3;III. Cognition and Aging;40
8.4;IV. Subcortical Strokes and Cognitive Impairment;41
8.5;V. Pathophysiology of Cognitive Impairment in Subcortical Vascular Lesions;43
8.6;VI. Treatment and Prevention;45
8.7;References;46
9;Chapter 3: Cerebrovascular and Cardiovascular Pathology in Alzheimer's Disease;52
9.1;I. Introduction;52
9.2;II. Risk Factors to AD;54
9.3;III. Conclusions;62
9.4;Acknowledgment;63
9.5;References;63
10;Chapter 4: Neuroimaging of Cognitive Impairments in Vascular Disease;66
10.1;I. Introduction;67
10.2;II. Vascular Cognitive Impairment;75
10.3;III. Updates on Neuroimaging Techniques in VCI;84
10.4;IV. Conclusions;90
10.5;Acknowledgments;91
10.6;References;91
11;Chapter 5: Contributions of Neuropsychology and Neuroimaging to Understanding Clinical Subtypes of Mild Cognitive Impairment;98
11.1;I. Introduction;99
11.2;II. Neuropsychological Presentation;100
11.3;III. Stability of Diagnosis;102
11.4;IV. Conversion to Dementia;102
11.5;V. MCI and Health Variables;103
11.6;VI. Daily Functioning and MCI;105
11.7;VII. Neuroimaging;106
11.8;VIII. Treatment;110
11.9;IX. Conclusions;112
11.10;Acknowledgments;114
11.11;References;114
12;Chapter 6: Proton Magnetic Resonance Spectroscopy in Dementias and Mild Cognitive Impairment;122
12.1;I. Introduction;123
12.2;II. Metabolites in 1H MRS;123
12.3;III. 1H MRS Findings in Dementias;125
12.4;IV. Discussion;138
12.5;Acknowledgments;141
12.6;References;141
13;Chapter 7: Application of Pet Imaging to Diagnosis of Alzheimer's Disease and Mild Cognitive Impairment1;150
13.1;I. Background;151
13.2;II. Application of PET to Primary and Specialty Care Settings;155
13.3;III. Appropriate Use of PET;157
13.4;IV. Summary;162
13.5;References;162
14;Chapter 8: The Molecular and Cellular Pathogenesis of Dementia of the Alzheimer's Type: An Overview;168
14.1;I. Introduction;168
14.2;II. Cellular Pathogenesis and Investigational Strategies;169
14.3;III. Molecular and Genetic Studies Resulting in Therapeutic Strategies;172
14.4;References;178
15;Chapter 9: Alzheimer's Disease Genetics: Current Status and Future Perspectives;184
15.1;I. Introduction: The Genetic Dichotomy of Alzheimer's Disease;185
15.2;II. Genome-Wide Association Studies in AD;186
15.3;III. Systematic Field Synopsis and Meta-Analyses: The AlzGene Database;189
15.4;IV. Strengths and Limitations of the AlzGene Approach;192
15.5;V. Assessment of Case-Control Associations Using Family-Based Methods;193
15.6;VI. Conclusions;196
15.7;Acknowledgments;197
15.8;References;198
16;Chapter 10: Frontotemporal Lobar Degeneration: Insights from Neuropsychology and Neuroimaging;202
16.1;I. Introduction;203
16.2;II. Classification of FTLD Subtypes and Their Features;207
16.3;III. Neuropsychological Assessment;209
16.4;IV. Neurobehavioral Assessment;214
16.5;V. Neuroimaging of FTLD;216
16.6;VI. Summary;224
16.7;References;224
17;Chapter 11: Lewy Body Dementia;232
17.1;I. Introduction;233
17.2;II. DLB Clinical Features;235
17.3;III. PD-D;237
17.4;IV. DLB and PD-D;238
17.5;V. Pathology;238
17.6;VI. Genetics;240
17.7;VII. Biomarkers;241
17.8;VIII. Management;242
17.9;References;243
18;Chapter 12: Dementia in Parkinson's Disease;246
18.1;I. Introduction;246
18.2;II. Epidemiology;247
18.3;III. Early Cognitive Changes in Parkinson's Disease;248
18.4;IV. Clinical Features of Parkinson's Disease Dementia;250
18.5;V. Pathology;252
18.6;VI. Neuroimaging;253
18.7;VII. Diagnosis;254
18.8;VIII. Treatment;254
18.9;References;256
19;Chapter 13: Early Onset Dementia;262
19.1;I. Introduction;263
19.2;II. Diagnostic Approach;263
19.3;III. Differential Diagnosis;266
19.4;References;278
20;Chapter 14: Normal Pressure Hydrocephalus1;280
20.1;I. History;281
20.2;II. Physical Examination;283
20.3;III. Laboratory Serologies;285
20.4;IV. Neuroimaging;285
20.5;V. Modern Diagnostic Criteria;286
20.6;VI. Treatment;290
20.7;VII. Predictors of Response to Shunting in Normal Pressure Hydrocephalus;291
20.8;VIII. Recent Work;292
20.9;References;296
21;Chapter 15: Reversible Dementias;300
21.1;I. Introduction;300
21.2;II. Etiologies;304
21.3;III. Nutritional Abnormalities;305
21.4;IV. Endocrine Disorders and Cognition;306
21.5;References;316
22;Index;320
23;Contents of Recent Volumes;328
24;Color Plates;356